-
20世纪70年代, 美国布鲁克海文国家实验室的Tatsuo Ido首先完成了18F-FDG的合成。1976年, 国立卫生研究院、宾夕法尼亚大学和布鲁克海文国家实验室合作首次合成并将这种化合物应用于两名正常人志愿者。由此, 人们将18F-FDG应用于多种疾病, 特别是肿瘤相关疾病的诊断。理清FDG代谢的原理有利于更准确的影像诊断, 因此, 现对FDG代谢分子机制的近年来研究进展做如下综述。
18F-FDG代谢显像相关分子机制的研究进展
Progress of molecular mechanism of 18F-FDG metabolism imaging
-
摘要: 18F-FDG作为最常用的PET-CT显像剂,被广泛应用于肿瘤显像。吸收和利用葡萄糖可以由多因素控制,它们都参与到肿瘤有氧糖酵解的增加,转移性肿瘤对FDG摄取普遍增加的现象提示它可能是必需的。高糖代谢是癌变的重要组成部分,因为糖代谢的增加产生了大量酸,酸给癌细胞提供生长的环境。理清FDG代谢的原理有利于更准确的影像诊断,与肿瘤对FDG高摄取相关的葡萄糖代谢主要分子机制包括葡萄糖转运蛋白和己糖激酶、线粒体缺陷、c-myc、缺氧诱导因子等。Abstract: 18F-FDGis the most common PET-CTimagingagent, which is widelyused in tumor inaging. Absorption and utilization ofglucose can be controlled bymultiple factors, which are involved in the increase in aerobic glycolysis of tumor.The phenomenon of a general increase uptake of FDG in metastatic tumor may indicate that it is necessary.High glucose metabolism is an important sign of cancer because increased glucose metabolism produces acid, which provide the growth environment to cancer cells.It is important to know the principle of FDG metabolism for accurate image diagnosis.This article reviews the progress of relevant molecular mechanism in recent years.The major molecular mechanism of glucose metabolism associated with tumor FDG uptake include glucose transport and hexokinase, mitochondrial defects, c-myc, hypoxia-inducible factor and so on.
-
Key words:
- Fluorodeoxyglucose F18 /
- Glycolysis /
- Neoplasms
-
[1] Warburg O. On the origin of cancer cells. Science, 1956, 123(3191): 309-314. doi: 10.1126/science.123.3191.309 [2] Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med, 2008, 49(Suppl 2): 24S-42S. doi: 10.2967/jnumed.107.047258 [3] Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med, 2001, 42(5 Suppl): 1S-93S. [4] 孟晓云, 陈跃. 葡萄糖转运蛋白的调控与疾病. 医学综述, 2008, 14(14): 2097-2100. doi: 10.3969/j.issn.1006-2084.2008.14.006
[5] 赵迎超, 伍钢. 己糖激酶与恶性肿瘤关系的研究进展. 肿瘤防治研究, 2006, 33(9): 694-696. doi: 10.3971/j.issn.1000-8578.884
[6] Rho M, Kim J, Jee CD, et al. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res, 2007, 27(1A): 251-258. [7] Hervouet E, Godinot C. Mitochondrial disorders in renal tumors. Mitochondrion, 2006, 6(3): 105-117. doi: 10.1016/j.mito.2006.03.003 [8] López-Rios F, Sánchez-Aragó M, García-García E, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res, 2007, 67(19): 9013-9017. doi: 10.1158/0008-5472.CAN-07-1678 [9] Isidoro A, Casado E, Redondo A, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis, 2005, 26(12): 2095-2104. doi: 10.1093/carcin/bgi188 [10] Zhang H, Gao P, Fukuda R, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell, 2007, 11(5): 407-420. doi: 10.1016/j.ccr.2007.04.001 [11] Kroemer G. Mitochondria in cancer. Oncogene, 2006, 25(34): 4630-4632. doi: 10.1038/sj.onc.1209589 [12] Mazure NM, Chauvet C, Bois-Joyeux B, et al. Repression of alphafetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res, 2002, 62(4): 1158-1165. [13] Kim JW, Gao P, Liu YC, et al. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol, 2007, 27(21): 7381-7393. doi: 10.1128/MCB.00440-07 [14] Benassi B, Fanciulli M, Fiorentino F, et al. C-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell, 2006, 21(4): 509-519. doi: 10.1016/j.molcel.2006.01.009 [15] Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem, 2000, 275(29): 21797-21800. doi: 10.1074/jbc.C000023200 [16] 杨盛力, 张万广, 陈孝平, 等. 缺氧诱导因子-1与缺氧诱导因子-2同肿瘤关系的比较. 肝胆外科杂志, 2007, 15(6): 471-474. doi: 10.3969/j.issn.1006-4761.2007.06.029
[17] Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res, 2005, 11(8): 2875-2878. doi: 10.1158/1078-0432.CCR-04-2142 [18] Knobbe CB, Trampe-Kieslich A, Reifenberger G. Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol, 2005, 31(5): 486-490. doi: 10.1111/j.1365-2990.2005.00660.x [19] Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res, 2005, 65(23): 10669-10673. doi: 10.1158/0008-5472.CAN-05-2620 [20] Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res, 2006, 12(10): 3019-3027. doi: 10.1158/1078-0432.CCR-05-2187 [21] Or YY, Hui AB, Tam KY, et al. Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. Int J Oncol, 2005, 26(1): 49-56. [22] Nyakern M, Tazzari PL, Finelli C, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia, 2006, 20(2): 230-238. doi: 10.1038/sj.leu.2404057 [23] Li J, Simpson L, Takahashi M, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT protein kinase B oncogene. Cancer Res, 1998, 58(24): 5667-5672. [24] Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell, 2000, 100(4): 387-390. doi: 10.1016/S0092-8674(00)80674-1 [25] Buzzai M, Bauer DE, Jones RG, et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene, 2005, 24(26): 4165-4173. doi: 10.1038/sj.onc.1208622 [26] Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer, 2002, 2(7): 489-501. doi: 10.1038/nrc839 [27] Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science, 2006, 312(5780): 1650-1653. doi: 10.1126/science.1126863 [28] Bensaad K, Vousden KH. p53: new roles in metabolism. Trends Cell Biol, 2007, 17(6): 286-291. doi: 10.1016/j.tcb.2007.04.004 [29] Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 2006, 126(1): 107-120. doi: 10.1016/j.cell.2006.05.036 [30] Green DR, Chipuk JE. p53 and metabolism: Inside the TIGAR. Cell, 2006, 126(1): 30-32. doi: 10.1016/j.cell.2006.06.032
计量
- 文章访问数: 1985
- HTML全文浏览量: 776
- PDF下载量: 3